Have Gilead's Gains Evaporated in the Coronavirus Treatment Race?

Adria Cimino, The Motley Fool
·4-min read
Have Gilead's Gains Evaporated in the Coronavirus Treatment Race?

Gilead Sciences (NASDAQ: GILD) started the year strong. As a result, while the rest of the stock market slid, Gilead did just the opposite. To make matters worse, the World Health Organization (WHO) recently advised against using remdesivir as a treatment for COVID-19.